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ABSTRACT 
22-Oxacalcitriol [1,25-(OH)Z-220xa-D3] mimics the action of 1,25- 
dihydroxyvitamin D3 [1,25-(OH),D,] in a variety of target tissues, 
including the systemic control of calcitriol metabolism. Similar to 1,25- 
(OH)1D3, 1,25-(OH)Z-220xa-D3 decreases the rate of 1,25-(OH)2D3 syn- 
thesis and accelerates its metabolic clearance rate. We have previously 
shown that in normal human monocytes, physiological concentrations 
of 1,25-(OH)*D3 and 1,25-(OH)2-220xa-D3 determine identical suppres- 
sion of 1,25-(OH)*D3 synthesis. Moreover, both sterols have a similar 
potency to induce vitamin D degradation through stimulation of the 
C24-hydroxylation pathway. In this study, we examined the ability of 
normal human monocytes to metabolize 1,25-(OH)2-220xa-D3 and 
whether the enzymes involved are the same as those that catabolize 
1,25-(OH)2D3. Time-course experiments demonstrated no detectable 
basal catabolic activity. However, exogenous 1,25-(OH)QDa at physio- 
logical concentrations induced 1,25-(OH)2-220xa-D3 degradation by 
normal human monocytes. Competition experiments showed that a lo- 
fold molar excess of unlabeled 1,25-(OH)*D3 inhibited tritiated-1,25- 
(OH)2-220xa-D3 catabolism by 85%, whereas a lo-fold excess of unla- 
beled 1,25-(OH)2-220xa-D3 reduced tritiated-1,25-(OH)2-220xa-D3 ca- 
tabolism by 33%. In contrast, although a lo-fold excess of unlabeled 
1,25-(OH)2D3 reduced tritiat=ed 1,25-(OH)2D3 catabolism by 60%, a 
1000-fold excess of 1,25-(OH)2-220xa-D3 was required to reduce triti- 
ated 1,25-(OH)*D3 catabolism to this degree. The apparent K, for 1,25- 
(OH)2-220xa-D3 was significantly higher than that of 1,25-(OH)*D3 (2.0 
rt 0.8 us. 0.9 -t 0.2 nM, respectively; P < 0.001) for the catabolic pathway 
induced by physiological concentrations of 1,25-(OH)2D3. Moreover, 
the presence of 0.65 nM lr25-(OH)ZD3 caused an additional increase in 
the K, for 1,25-(OH)Z-220xa-D3 (3.2 rf: 0.8 nM). These data suggest 
that 1,25-(OH)z-220xa-D3 may be less accessible than 1,25-(OH)zD3 to 
the hydroxylases involved in vitamin D catabolism. The resulting 
prolonged biological half-life of the analog in certain target tissues may 
be involved in its selectivity. (Endocrinology 133: 2719-2723, 1993) 
T HE ENZYMATIC conversion of 25-hydroxyvitamin D3 (250HD$ to 1,25dihydroxyvitamin D3 [1,25-(OH)2D3] 
is the most important step in vitamin D metabolism. Al- 
though 1,25-(OH)*D3 is produced primarily in the kidney, 
extrarenal 1,25-(OH)*D3 synthesis has been reported in vitro 
in placenta (1, 2), osteoclasts derived from bone marrow 
macrophages (3), keratinocytes (4, 5), and macrophages from 
sarcoid (6) and tuberculous granulomata (7). In bone marrow 
and alveolar macrophages from normal humans, 25-hydrox- 
ycholecalciferol la-hydroxylase can be induced by treatment 
with y-interferon or lipopolysaccharide (B-10). The high 
intracellular 1,25-(OH)*D3 levels in activated macrophages 
induce the production of 24,25-(OH)2D3 (10). 
Our laboratory has demonstrated that monocytes derived 
from peripheral blood mononuclear leukocytes from normal 
subjects can convert 25(OH)D3 to 1,25-(OH),D, (11). Exog- 
enous 1,25-(OH)*D3 inhibits 1,25-(OH)zD3 synthesis and 
stimulates 1,25-(OH)?D3 catabolism in a dose-dependent 
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fashion (11, 12). Four-hour exposure of normal human mac- 
rophages to a physiological (0.24 nM) concentration of the 
sterol reduces macrophage la-hydroxylase activity and stim- 
ulates the synthesis of metabolites more polar than 1,25- 
(OH)zDs (13). 
In kidney and intestine, C-24 oxidation of 1,25-(OH)2D3 
is the major metabolic pathway involved in the inactivation 
of circulating 1,25-(OH)2D3 (14, 15). Previous studies in our 
laboratory have demonstrated that in normal human periph- 
eral monocytes (NHPM), exogenous 1,25-(OH)2D3 induces 
its own catabolism through activation of the C-24 hydrox- 
ylation pathway (13). 
The vitamin D analog 22-oxacalcitriol [1,25-(OH)z-220xa- 
D3] mimics 1,25-(OH)*D3 in the control of systemic calcitriol 
homeostasis. It inhibits 1,25-(OH)zDs synthesis in rat kidney 
cells (16). Moreover, it has a potency similar to that of 1,25- 
(OH)*D3 to induce catabolism and suppress 1,25-(OH)2D3 
generation by normal macrophages (13). On the other hand, 
1,25-(OH)2-220xa-D3 is 10 times more potent than 1,25- 
(OH)*D3 in suppressing cell growth and inducing differentia- 
tion of the mouse myelocytic leukemic cell line WEHI- (17, 
18), and it enhances the immune response with a potency 
50 times higher than 1,25-(OH)2D3 in mice (19). In psoriatic 
fibroblasts, 1,25-(OH)2-220xa-D3 inhibited growth more ef- 
fectively than 1,25-(OH)2D3 (20). On the contrary, 1,25- 
(OH)2-220xa-D3 has much lesser direct effects on bone me- 
tabolism in normal male rats than 1,25-(OH)*D3 (21). Our 
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laboratory has also demonstrated that the administration of 
170 ng 1,25-(OH)2-220xa-D3/100 g BW to rats for 4 days did 
not cause the hypercalcemia (22). The mechanisms respon- 
sible for the diverse biological activity are still controversial. 
The affinity of 1,25-(OH)2-220xa-D, for the 1,25-(OH)2D3 
receptor (VDR) in HL60 cells is one tenth that of 1,25- 
(OH)*D) (17). However, the analog exhibits a more potent 
activity than 1,25-(OH)2D3 in inducing cell differentiation 
(20) and more enhanced immunoregulating effects (19). The 
affinities of the vitamin D analogs for VDR are, therefore, 
not necessarily correlated with their biological activities. It is 
possible that other factors, such as cellular uptake, intracel- 
lular metabolism, and, therefore, the biological half-life of 
vitamin D compounds in different target tissues, are impor- 
tant for their selectivity. 
With regard to cellular uptake, it has been shown that the 
binding affinity of 1,25-(OH),-22oxa-D, for serum vitamin 
D-binding protein (DBP) is much lower than that of 1,25- 
(OHhD3 (12, 19, 23). The lower affinity of 1,25-(OH)*D3- 
22oxa-D3 for DBP results in a higher proportion of the free 
form of the sterol in the circulation (12); therefore, in the 
presence of serum, 1,25-(OH)2-220xa-D3 is more effective 
than 1,25-(OH)*D3 in inducing vitamin D catabolism in nor- 
mal macrophages (12). 
The present studies were focused on intracellular metab- 
olism. We compared the abilities of normal human mono- 
cytes to catabolize 1,25-(OH)2-220xa-D3 and 1,25-(OH)zD3. 
Materials 
Materials and Methods 
1,25-(OH)2D3 was kindly provided by Dr. Milan Uskokovic (Hoffman 
LaRoche, Nutley, NJ). l,25~Dihydroxy[26,27-methyl-3H]cholecalciferol 
(SA, 174 Ci/mmol) was obtained from Amersham (Arlington 
Heights, IL). i,25-(dH)2-220xa-D,) and 22-oxa-[26-3H]calcihiol @A, 
86.3 Ci/mmol) were synthesized by Chugai Pharmaceuticals (Tokyo, 
Japan). 
Culture of human monocytes 
Peripheral blood was obtained from normal volunteers by venipunc- 
hue. Mononuclear leukocytes were isolated by Ficoll-Hypaque separa- 
tion (Pharmacia LKB Biotechnoloav, Inc., I’iscatawav, NT). Cells were 
plated in six-well plates at a concentration of 7 X 10b’cells/well in 1 ml 
RPMI-1640 with 1% fatty acid-free albumin, 50,000 U/liter penicillin G 
sodium, 50,000 &liter streptomycin sulfate, 10 mM HEPES, and 0.8 
mu sodium bicarbonate. Cells were maintained at 37 C in a humidified 
atmosphere containing 95% air-5% COz. After an incubation period of 
18 h, nonadherent cells and media were removed. More than 95% of 
the adherent cells stained positively for monocyte-macrophage-specific 
a-naphtyl acetate esterase activity. Adherent cells were washed once 
with PBS and twice with RI’MI-1640 containing 0.1% fatty acid-free 
albumin. One milliliter of RPMI-1640 (0.1% fatty acid-free albumin) 
was then added to adherent cells. Assays for 1,25-(OH)2-220xa-D1 or 
1,25-(OHhDs catabolism were initiated by the addition of 0.26 nM [3H] 
1,25-(OH),.-22oxa-D3 or [3H]1,25-(OH)2D3, respectively. The reaction 
was stopped after 1 h of incubation at 37 C with 1 ml acetonitrile. To 
quantitate recoveries, 100 ng radioinert 1,25-(OH)z-220xa-D3 or 1,25- 
(OH)*Ds were added to the samples for 1,25-(OH)z-220xa-D, and 1,25- 
(OH)*D, catabolism experiments, respectively. Samples were extracted 
using Cls cartridges (Fisher Scientific, Fair Lawn, NJ), as described by 
Reinhardt et al. (24), and further purified on normal phase HPLC (4.5 
mm x 25 cm Zorbax-Sil; 4.5 pm; Phenomenex, Torrance, CA), using 
methylene chloride-isopropanol (97:3). One-milliliter fractions eluting 
with 1,25-(OH)?D3 or 1,25-(OH)Z-220xa-D3 were collected, dried, mixed 
with 3 ml Scintiverse BD (Fisher Scientific), and counted for tritium (ICN 
Micrometic System, Inc., Huntsville, AL). Counts per min were corrected 
for recovery using the area of UV absorption peak of the internal 
standard. Results were normalized to DNA content of cells, measured 
in the pellets of the extraction procedure using the ethidium bromide 
method (25), and expressed as femtomoles of metabolite per rg DNA. 
Effect of exogenous 1,25-(OHJ2D3 on the catabolism of 1,25- 
(OH)2-220xa-D:i by normal human monocytes 
Exogenous 1,25-(OHbD3, at a concentration of 0.24 nM, was added 
to 
10 r 
eripheral blood mononuclear cells plated at a concentration of 7 X 
cells in 1 ml RPMI-1640 containing 1% fatty acid-free albumin. Cells 
were incubated at 37 C for 18 h with or without 0.24 nM 1,25-(OH)zD3. 
Adherent cells were washed, and 0.26 nM [3H]-1,25-(OH)2-220xa-D3 
was added in 1 ml medium. The amount of 13H11.25-(OH&22oxa-Dt 
remaining was measured, as indicated above, a’t 0: 6.5, i, 2,‘3, 4, 6, and 
12 h. For each time point, determinations were performed in triplicate. 
Competition experiments 
Competition experiments [tritiated 1,25-(OH)zD3 with radioinert 1,25- 
(OHh-22oxa-D3 and tritiated 1,25-(OHh-22oxa-Da with radioinert 1,25- 
(OH)2D1] were carried out in peripheral blood mononuclear cells that 
had been pretreated for 18 h with 0.24 nM 1,25-(OH)zD3 to induce the 
catabolic pathway. The adherent cells were washed and incubated with 
0.26 nM [3H]1,25-(OH)2-220xa-D3 alone or in the presence of 2.6 nM 
radioinert 1,25-(OH)z-22oxa-D3 or 1.3 or 2.6 HIM radioinert 1,25-(OH)2D3. 
Catabolism of [‘H]1,25-(OH)2D3 (0.26 nM) was measured in the presence 
of 2.6 nM radioinert 1,25-(OH)zD3 or 2.6 or 260 nM radioinert 1,25- 
(OHh-22oxa-D3. The reaction was stopped, as previously indicated, 
after 1 h of incubation at 37 C. The fraction coeluting with authentic 
1,25-(OHhD3 or 1,25-(OH)z-220xa-D3 in normal phase HPLC was dried 
and counted for hitium. Determinations were performed in triplicate for 
each experimental condition, corrected per rg DNA in the sample, and 
expressed as femtomoles of metabolite per rg DNA. The percent 1,25- 
(OH)zD3 or 1,25-(OH)?-22oxa-D, catabolized was calculated as follows: 
% of catabolism = [(A - B)/A] X 100, where A represents femtomoles 
of [3H]1,25-(OH)2D3 or 1,25-(OH)2-220xa-D3 in control wells at time 
zero, and B represents femtomoles of 1,25-(OH)zDa or 1,25-(OHh- 
22oxa-D3 in experimental wells after l-h incubation. 
Kinetic analysis 
Four different substrate concentrations (0.13,0.26, 0.52, and 0.78 nM) 
were assayed in triplicate to determine the K, for 1,25-(OH)zD3 and 
1,25-(OHh-22oxa-D, and the respective maximal velocities (V,,) of the 
enzymes involved in vitamin D catabolism. K, and V,, were obtained 
using the double reciprocal plot of Lineweaver and Burk with linear 
regression analysis of the data. The inhibitory effect of 1,25-(OH)zDa on 
1,25-(OH),-22oxa-D, catabolism was also tested using 0.13, 0.26, 0.52, 
and 0.78 nM tritiated 1,25-(OH)Z-220xa-D3 as substrate in the presence 
of 0.65 nM radioinert 1,25-(OHhD3 in the incubation medium. 
Statistical analysis 
Results are expressed as the mean + SEM. Statistical evaluation of the 
data was performed by Student’s t test for unpaired observations. 
Results 
The time course for 1,25-(OH)>-22oxa-D3 catabolism is 
depicted in Fig. 1. Macrophages obtained from four normal 
volunteers were examined. No degradation of 1,25-(OH)z- 
22oxa-D3 could be detected in the first 2 h (Fig. 1, -). 
Thereafter, the amount of [3H]1,25-(OH)2-220xa-D3 remain- 
ing in the well decreased linearly. By 4 h, 57.8 + 1.6% of 
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Time (hours) 
FIG. 1. Time course for 1,25-(OH&22oxa-D3 catabolism by normal 
human mononuclear leukocytes. Peripheral blood mononuclear cells 
were incubated in serum-free medium with (0) or without (A) exoge- 
nous 1,25-(OH)2Da (0.24 nM) for 18 h. Nonadherent cells and media 
were removed. Adherent cells were incubated for the specified time 
with 0.26 nM tritiated 1,25-(OH),-22oxa-D3. Remaining tritiated 1,25- 
(OH)2-220xa-D3 was measured as outlined in Materials and Methods. 
Results are expressed as the percentage of 1,25-(OH)2-220xa-D3 catab- 
olized. Values are the mean and SEM of four independent experiments. 
Experiments were performed in triplicate. *, Differs from control (time 
zero), P < 0.001. OCT, 1,25-(OH)z-220xa-Ds. 
1,25-(OH)2-220xa-D3 had been catabolized. This suggests 
that 1,25-(OH)2-220xa-D3 at 0.26 nM can induce its own 
catabolism through a genomic effect. 
When the enzyme(s) responsible for vitamin D catabolism 
was induced by preincubation of NHPM with 0.24 nM 1,25- 
(OH)*D3 for 18 h, 1,25-(OH)z-220xa-D3 catabolism was ac- 
celerated (Fig. 1, - - -). After l-h incubation, 47.1 k 0.9% (n 
= 4) of the 1,25-(OH)z-220xa-D3 was catabolized, and more 
than 95% was degraded after 6 h. 
To test whether 1,25-(OH)2D3 and 1,25-(OH),-22oxa-D, 
followed the same catabolic pathway, competition experi- 
ments were performed with cells from normal volunteers 
after induction of catabolic pathways by an 18-h exposure 
to 0.24 nM exogenous 1,25-(OHbD3. Results of the experi- 
ments of 1,25-(OH)2-220xa-D3 catabolism are shown in Fig. 
2. Control cells were incubated with 0.26 nM [3H]1,25-(OH)2- 
22oxa-D3, as indicated in Materials and Methods, and after 1 
h, 44.8 + 2.3% (n = 9) of the 1,25-(OH),-22oxa-D3 had been 
catabolized (P < 0.05). Inclusion of 2.6 nM radioinert 1,25- 
(OH)2-220xa-D3 reduced degradation of [3H]1,25-(OH)z- 
220xaD3 catabolism to 30.2 + 1.7% (n = 5) during the l-h 
incubation (P < 0.01). Competition with 2.6 nM 1,25-(OH)*D3 
almost completely blocked the catabolism of [3H]1,25-(OH)s- 
22oxa-D3(6.8 f 0.2% degraded; n = 5; P < 0.001). Coincu- 
bation with 1.3 nM 1,25-(OH)2D3 for 1 h markedly inhibited 
1,25-(OH)2-220xa-D3 catabolism (19.2 -C 2.3% degraded; n 
= 5; P < 0.01). 
The effect of radioinert 1,25-(OH)z-220xa-D3 on the catab- 
olism of [3H]1,25-(OH)zD3 by NHPM is shown in Fig. 3. 
Experiments were performed after preincubation of periph- 
eral blood mononuclear cells with 0.24 nM 1,25-(OH),D, for 
18 h to induce catabolism. Adherent cells were incubated 
Control OCT 1,25(OH),D 1,25mi),D 
2.6 nM 1.3 nM 2.6 nM 
FIG. 2. Inhibition of tritiated 1,25-(OH)2-220xa-D3 catabolism by ra- 
dioinert 1,25-(OH)2-220xa-D3 and 1,25-(OH)*D3. Peripheral blood 
mononuclear cells were incubated for 18 h with 0.24 nM radioinert 1,25- 
(OH),D,. Nonadherent cells and media were removed. Adherent cells 
were incubated for 1 h with 0.26 nM tritiated 1,25-(OH)2-220xa-D3 
(control; n = 9) in the presence of 2.6 nM radioinert 1,25-(OH)2-220xa- 
D3 (n = 5) or either 1.3 nM (n = 5) or 2.6 nM radioinert 1,25-(OH)*D3 
(n = 5). The tritiated 1,25-(OH)2-220xa-D3 remaining was measured as 
outlined in Materink and Methods. Results are expressed as the per- 
centage of 1,25-(OH)2-220xa-D3 catabolized in 1 h. Values are the mean 
and SEM. Experiments were performed in triplicate. *, Differs from 
control, P < 0.001. **, Differs from 1,25-(OH)z-220xa-D3 (2.6 nM), P < 
0.01. ***Differs from 1,25-(OH)2-220xa-D3 (2.6 nM), P < 0.001. OCT, 
1,25-(OH)2-220xa-D:1; 1,25-(OH),D, lr25-(OH)2D3. 
Control 1.25mi1,D OCT OCT 
2.6 nM 2.6 nM 260 nh4 
FIG. 3. Inhibition of tritiated 1,25-(OH)*D3 catabolism by radioinert 
1,25-(OH)*Da and 1,25-(OH)2-220xa-D3. Peripheral blood mononuclear 
cells were incubated for 18 h with 0.24 nM radioinert 1,25-(OH)2D3. 
Nonadherent cells and media were removed. Adherent cells were in- 
cubated for 1 h with 0.26 nM tritiated 1,25-(OH)*D3 (control; n = 8) in 
the presence of 2.6 nM radioinert 1,25-(OH),D, (n = 4) or either 2.6 
nM (n = 4) or 260 nM radioinert 1,25-(OH)2-220xa-D3 (n = 4). The 
tritiated 1,25-(OH),D, remaining was measured as outlined in Materials 
and Methods. Results are expressed as the percentage of 1,25-(OH)2Ds 
catabolized in 1 h. Values are the mean and SEM. Experiments were 
performed in triplicate. *, Differs from control, P < 0.01. OCT, 1,25- 
(OH)2-220xa-D3; 1,25-(OH)*D, 1,25-(OHhD3. 
with 0.26 nM [3H]1,25-(OH)2D3 for 1 h, as indicated in 
Materials and Methods. In controls, 49.9 + 4.4% (n = 8) of 
the [3H]1,25-(OH)2D3 was catabolized. Inclusion of 2.6 nM 
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radioinert 1,25-(OH)2D3 reduced catabolism to 18.9 t 3.2% 
(n = 4) during l-h incubation (P < 0.01). Inclusion of 2.6 nM 
1,25-(OH)2-220xa-D3 did not affect 1,25-(OH)2D3 catabolism 
(n = 4). A concentration of 1,25-(OH)2-220xa-D3 (260 nM) 
1000 times higher than that of the [3H]1,25-(OH)2D3 reduced 
degradation by only 20.1 f 3.3% (n = 4). These results 
suggested that the hydroxylases involved in the catabolic 
pathway stimulated by exogenous 1,25-(OHhD3 in NHPM 
have a lower affinity for 1,25-(OH)z-220xa-D3 than for 1,25- 
(OH)Dz. 
Table 1 shows the kinetic parameters for the catabolism 
of 1,25-(OHhD3 and 1,25-(OH)z-220xa-D, by NHPM. The 
K, for 1,25-(OH)2-220xa-D3 of the enzymes of the catabolic 
pathway was significantly higher than that for 1,25-(OHhD3 
(P < 0.001). The V,,, of 1,25-(OH)2-220xa-D3 was slightly, 
but significantly, higher than that of 1,25-(OHhD, (P < 0.05). 
We also examined K, and V,,, when NHPM were coincu- 
bated with [3H]-1,25-(OH)2-220xa-D3 (0.13, 0.26, 0.52, and 
0.78 nM) and nonradioactive 1,25-(OHhD3 (0.65 nM). The K, 
for 1,25-(OH)2-220xa-D3 was further increased to 3.2 + 0.8 
nM (n = 5; P < O.OOl), without significant changes in the 
V,,,. 
Discussion 
Our laboratory has demonstrated that 1,25-(OH)z-220xa- 
D3 lowers serum 1,25-(OHbD3 levels in normal rats by a 
mechanism independent of PTH suppression (26). 1,25- 
(OHh-22oxa-D3 mimics 1,25-(OH)*D3 in the induction of the 
enzymatic processes involved in 1,25-(OH)2D, degradation, 
increasing the MCR of the sterol. It also suppresses renal 
1,25-(OHhD3 synthesis in normal animals (16). We have 
reported that 0.24 nM 1,25-(OH)2-220xa-D3 has a potency 
similar to that of 1,25-(OH),D, in inducing catabolism and 
suppressing 1,25-(OH)sD3 synthesis by normal human pe- 
ripheral macrophages (13). Clearly, 1,25-(OH)r-22oxa-D, 
mimics 1,25-(OH)*D3 in the control of systemic and extrare- 
nal vitamin D metabolism. The lower affinity of 1,25-(OH)*- 
22oxa-D3 for DBP results in a higher proportion of the free 
active form in serum and a more rapid clearance from the 
TABLE 1. Kinetic parameters of 1,25-(OH)z-220xa-Ds and 1,25- 
(OH)*D3 catabolism by normal human mononuclear leukocytes 
1,25-(OH)2D3 (n = 4) 0.9 f  0.2 37.0 + 3.0 
1,25-(OH)Z-220xa-D3 (n = 6) 2.0 k 0.8” 58.2 It 3.4b 
1,25-(OH)z-220xa-D3 + 1,25-(OH),D, 3.2 + 0.8’ 59.3 + 1.5 
(n = 5) 
Normal human peripheral monocytes were incubated with increas- 
ing concentrations (0.13, 0.26, 0.52, and 0.78 nM) of tritiated 1,25- 
(OH)2-220xa-D3 or 1,25-(OH)*D3. K, and V,., were obtained using the 
double reciprocal plot of Lineweaver and Burk with linear regression 
analysis. The inhibitory effect of 1,25-(OH)zDs on 1,25-(OHh-22oxa- 
Ds catabolism was tested with the four concentrations (0.13, 0.26, 0.52, 
and 0.78 nM) of tritiated 1,25-(OH)2-220xa-D3 and 0.65 nM radioinert 
1,25-(OH)*D3. Data are expressed as the mean f  SEM. n, Number of 
independent experiments. 
a Differs from 1,25-(OH)zDa, P < 0.001. 
b Differs from 1,25-(OHhD,, P < 0.05. 
‘Differs from 1,25-(OH)z-220xa-D3, P < 0.001. 
circulation (12). The higher proportion of free 1,25-(OHb- 
22oxa-D3 renders the analog more effective than 1,25- 
(OH)*D3 in stimulating vitamin D catabolism at various 
serum concentrations in NHPM (12). It is possible that pref- 
erential uptake of either the free or bound form by different 
target cells plays a role in the selectivity of 1,25-(OH)z-220xa- 
D3. In the intracellular catabolism of 1,25-(OH)*D3, the prev- 
alent pathway is C-24 oxidation (27-29), in which 1,25- 
(OH)*D3 is first hydroxylated at carbon 24 to render 1,24,25- 
(OH)*D3. Brown et al. (30) suggested that 1,25-(OH)2-220xa- 
D3 is metabolized by a pathway that is probably identical to 
the vitamin D-inducible side-chain oxidation pathway that 
degrades other vitamin D metabolites in bovine parathyroid 
cells. Both compounds compete for the same initial enzyme 
in the metabolic pathway, presumably the vitamin D-24 
hydroxylase. We have shown that 1,25-(OHhD3 induces its 
own degradation in NHPM through activation of the C-24 
oxidation pathway (13). 1,25-(OH)2-220xa-D, has a potency 
similar to that of the parent hormone to stimulate 1,25- 
(OHhD3 breakdown by macrophages. We have examined 
the ability of NHPM to metabolize 1,25-(OH)2-220xa-D3 and 
whether the analog competes with 1,25-(OH)*D3 for the 
hydroxylases involved in 1,25-(OH)zD3 degradation. Time- 
course experiments showed that there was no detectable 
basal activity of the hydroxylases involved in 1,25-(OH)*- 
22oxa-D3 catabolism in NHPM. However, after 3-h exposure 
to 0.26 nM 1,25-(OH)2-220xa-D3, we observed a significant 
induction of 1,25-(OH)2-220xa-D3 degradation. This suggests 
that 1,25-(OH)2-220xa-D3 induces its own catabolism 
through a genomic effect. 
Our competition experiments suggested that 1,25-(OH)*- 
22oxa-D3 is less accessible than 1,25-(OHhD3 for the en- 
zyme(s) involved in vitamin D catabolism. A lo-fold molar 
excess of 1,25-(OH)rD3 totally blocked 1,25-(OH)2-220xa-D3 
catabolism. 1,25-(OH)*D3 catabolism was not affected by the 
presence of a lo-fold molar excess of radioinert 1,25-(OHb- 
22oxa-D3; a lOOO-fold excess of 1,25-(OH)2-220xa-D3 was 
necessary to significantly reduce 1,25-(OH)rD3 degradation. 
K, determinations demonstrated that the apparent K, for 
1,25-(OH)z-220xa-D3 was higher than that for 1,25-(OHhD3. 
Moreover, coincubation of 1,25-(OH)2-220xa-D3 and 1,25- 
(OH),D, further increased the K, for 1,25-(OH)2-220xa-D,. 
However, this 2-fold difference in the K,s for 1,25-(OH)2D3 
and 1,25-(OH)2-220xa-D3 cannot explain the need for a 
lOOO-fold excess of radioinert 1,25-(OH)2-220xa-D3 to reduce 
1,25-(OHbD3 degradation by only 20%. It is apparent that 
other factors determine that when both metabolites are avail- 
able for the cells, 1,25-(OH),D, will be preferentially de- 
graded. A potential explanation is the existance of a delivery 
mechanism that markedly favors 1,25-(OHhD3 access to the 
intracellular organelles responsible for vitamin D catabolism. 
In summary, in normal peripheral monocytes, the hydrox- 
ylases involved in vitamin D catabolism have lower affinity 
for 1,25-(OH)2-220xa-D3 than 1,25-(OHhD3, with a resulting 
prolonged biological half-life of the analog. Clearly, the 
ability to degrade 1,25-(0H)2-220xa-D3 and 1,25-(OH)zDs 
differs between normal monocytes and parathyroid cells. 
Differential intracellular metabolism of 1,25-(OH)2-220xa-D3 
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in different target tissues may be an additional factor in- 
volved in the selectivity of the analogs. 
These results suggest a potential for 1,25-(OH)2-220xa-D3 
in the control of the hypercalcemia caused by deregulated 
calcitriol production in sarcoidosis and other granulomatoses. 
In peripheral monocytes, 1,25-(OH)2-220xa-D3 can block 
1,25-(OHhD3 synthesis and induce 1,25-(OH)*D3 catabolism 
with the same potency of 1,25-(OHhD3 (13). However, com- 
petition experiments showed that in the presence of a lOOO- 
fold excess of the analog, 1,25-(OH)*D3 will be catabolized 
preferentially. As this analog was reported to have very weak 
calcemic action (17, 19, 21), 1,25-(OH)2-220xa-D3 may pro- 
vide an alternative therapeutic maneuver to reduce serum 
calcitriol and, therefore, serum calcium in sarcoidosis and 
other granulomatoses without the alterations in the immune 
system and other side-effects caused by the classical treat- 
ment with glucocorticoids. 
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